1. CLINICAL AND PARACLINICAL FEATURES; EARLY RESULTS OF PACLITAXEL – CARBOPLATIN CHEMOTHERAPY IN TREATMENT THE STAGE IIIB – IV NON SMALL CELL LUNG CANCER AT THANH NHAN HOSPITAL
Nguyễn Thành Vinh
Hải Phòng, 2017

2. INTRODUCTION Lung cancer was the most common cancer worldwide
Vietnam has a high incidence of lung cancer in both sexes, ranking first in men and 5th in women.
Early diagnosis of lung cancer is difficult, most patients are diagnosed at late stage
Chemotherapy are still the choice to take palliative care and extend extra life in late-stage

3. To describe a variety of clinical features, paraclinical
AIM 1.
To describe a variety of clinical features, paraclinical 2.
Early results of Paclitaxel – Carboplatin chemotherapy in treatment the stage IIIB – VI NSCLC

4. METHOD
39 patients with stage IIIB – IV NSCLC were treated b Paclitaxel – Carboplatin regment at the Department of Oncology - Thanh Nhan Hospital from march 2015 to march 2016

5. METHOD Eligibility Criteria Histology: NSCLC Stage IIIB - IV PS: 0-1
First diagnosed, no perior chemotherapy
No contraindications to chemotherapy
Full medical record
Undergone 3 cycles chemotherapy at least

6. METHOD Ineligible criteria Histology: SLCC Brain metastases
Treatment before
Prior chemotherapy

7. METHOD Dose Paclitaxel – Carboplatin regment
Paclitaxel 175 mg/m2 IV d1
Carboplatin AUC = 6 IV d1
Every 3 weeks, at least 3 cycles

8. METHOD 4.Phân tích và xử lý số liệu 5.Đạo đức trong nghiên cứu
- Xử lý số liệu bằng phần mềm SPSS 16.0
5.Đạo đức trong nghiên cứu
Phác đồ nghiên cứu là phác đồ chuẩn
Có sự cho phép của bệnh viện Thanh Nhàn
Có sự đồng ý hợp tác của bệnh nhân.
Danh sách bệnh nhân không nêu tên.
Kết quả nghiên cứu chỉ để áp dụng phục vụ khám và điều trị cho bệnh nhân, không có mục đích nào khác

9. RESULTS 1. Patients Characteristics Table 1: Patients characteristics%
In total , 39 patients 39
100
Age
Mean
Range 57
33 – 77
Sex
Female
Male 5 34
12,8
87,2 PS 1 18 21
46,2
53,8
Histology
Adenocarcinoma
Squamous cell
Large cell 24 14
61,5
35,9
2,6
Stage
IIIB IV 26 13
66,7
33,3
CEA
< 5 ng/ml
>5 ng/ml 11 28
28,2
71.8

10. RESULTS 1. Patients Characteristics Table 2: Clinical symptoms%
Cough 17
43,5
Blood in sputum 8
20,5
Lymph nodes at neck
Chest pain 31
79,5
Trouble breathing 13
33,3
Weight loss 21
53,4
fever 3
7.7

11. RESULTS 2. Results Table 3: Respone rate n % Comeplete respone
Partial respone 12
30,8
Stable disease 20
51,3
Progressive disease 7
17,9
Total 39
100

12. RESULTS 2. Resullts Table 4: Stage Respone Stage Respone n %
n %
No respone
n %
Total
IIIB ,5 ,5
16 (100%) IV ,4 ,6
13 (100%) ,8 ,2
39 (100%)

13. RESULTS 2. Results Table 5: Histologic respone Respone Histology n %
n %
No respone
n %
Total
Adenocarcinoma ,8 ,2
(100%)
Squamous cell 76
(100%)
Large cell
(100%) ,9 ,1
(100%)

14. RESULTS 3. Side effects Table 6: Hematologic Toxicities Grade 0 n %
Grade 0
n %
Grade 1
Grade 2
Grade 3
Grade 4
Neutropenia ,1 ,6 ,3
Anemia ,1 ,1 ,8
Thrombocytopenia

15. RESULTS 3. Side effects Table 7: Nonhematologic toxicity Grade 0 n %
Grade 0
n %
Grade 1
n %
Grade 2
n %
Grade 3
Grade 4
Ure
Creatinin ,6 ,6
SGPT ,2 ,7 ,1
SGOT ,1

16. DISCUSION 1.Patient characteristics
In total 39 patients 34 male và 5 female , the average age 57 (range 33 to 77). Belani’s research, 2005, age at 64, Rosell’s reseach 2002 age at 58
24 patients had Adenocarcinoma (61.5%), Lê Quang Huy:46.7 %, Lê Thu Hà 42.2 %
Chest pain is common symptom, 31 patients 79.5 % ,Nguyễn Thị Minh Phương (2010) 82.5%, Vũ Văn Vũ (2002) 82.5 %.

17. DISCUSION 2. Respone rate
No patients had a complete response, partial response rate reached
Patients with advanced disease will stop treatment and change other regimens..

18. DISCUSION 3.Side effects Common Hematologic toxicities
4 patients had grade 3 neutronemia (10.3%)
5 patients had grad 3 anemia(12,8%)
No patiets had thrompocytopenia
Nonhematologic toxicities: toxicitíe on the liver, kidney is mild
Most side effects are acceptable and no patients stop treatment because of side effects

19. CONCLUSION
Paclitaxel – carboplatin chemotherapy is an effective and safe for patients with stage IIB – IV NSCLC

20. THANK YOU